Yanli Tao1, Tiejun Yuan2, Xuechang Li2, Shuqin Yang2, Fanping Zhang2, Li Shi3. 1. Department of Otolaryngology, Weifang People's Hospital Weifang, P. R. China ; Department of Otolaryngology, Qilu Hospital of Shandong University Jinan, P. R. China. 2. Department of Otolaryngology, Weifang People's Hospital Weifang, P. R. China. 3. Department of Otolaryngology, Qilu Hospital of Shandong University Jinan, P. R. China.
Abstract
OBJECTIVES: To investigate the therapeutic effects of OM-85 BV as an adjunctive treatment on experimental chronic rhinosinusitis (CRS) in mice. METHODOLOGY: Female BALB/c mice aged 8-12 weeks were sensitized and administrated by intranasal Aspergillus fumigatis (AF) three times per week for 1 week, 3 weeks, 2 months and 3 months (n = 10 each time point). The mice were randomly and equally assigned to four groups: normal control group, model group, OM-85-BV plus amoxicillin group, and isolated amoxicillin group. Inflammatory changes were determined by hematoxylin-eosin (HE) staining. The expression levels of suppressor of cytokine signaling (SOCS) 1, SOCS3, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ in samples were assessed by using real-time PCR (RT-PCR) and Western blotting. RESULTS: There were significantly inflammatory and structural changes between the model and other groups. Compared to the model group, the mRNA expression levels of SOCS1, SOCS3, TNF-α, and IFN-γ were significantly decreased in OM-85-BV plus amoxicillin group and isolated amoxicillin group, along with the protein levels. CONCLUSION: The bacterial extract OM-85 BV is a low-cost alternatively adjunctive drug to treat CRS with simple oral administration, good safety, and few side effects.
OBJECTIVES: To investigate the therapeutic effects of OM-85 BV as an adjunctive treatment on experimental chronic rhinosinusitis (CRS) in mice. METHODOLOGY: Female BALB/c mice aged 8-12 weeks were sensitized and administrated by intranasal Aspergillus fumigatis (AF) three times per week for 1 week, 3 weeks, 2 months and 3 months (n = 10 each time point). The mice were randomly and equally assigned to four groups: normal control group, model group, OM-85-BV plus amoxicillin group, and isolated amoxicillin group. Inflammatory changes were determined by hematoxylin-eosin (HE) staining. The expression levels of suppressor of cytokine signaling (SOCS) 1, SOCS3, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ in samples were assessed by using real-time PCR (RT-PCR) and Western blotting. RESULTS: There were significantly inflammatory and structural changes between the model and other groups. Compared to the model group, the mRNA expression levels of SOCS1, SOCS3, TNF-α, and IFN-γ were significantly decreased in OM-85-BV plus amoxicillin group and isolated amoxicillin group, along with the protein levels. CONCLUSION: The bacterial extract OM-85 BV is a low-cost alternatively adjunctive drug to treat CRS with simple oral administration, good safety, and few side effects.
Authors: Robin Lindsay; Tiffani Slaughter; Joy Britton-Webb; Steven R Mog; Rich Conran; Monica Tadros; Natalie Earl; David Fox; John Roberts; William E Bolger Journal: Otolaryngol Head Neck Surg Date: 2006-05 Impact factor: 3.497
Authors: Tae Hoon Kim; Kihyoung Kim; Se Jin Park; Seung Hoon Lee; Jae Woong Hwang; Sang Heon Park; Gun Hwee Yum; Sang Hag Lee Journal: Int Arch Allergy Immunol Date: 2012-04-04 Impact factor: 2.749
Authors: Se Jin Park; Tae Hoon Kim; Young Joon Jun; Seung Hoon Lee; Hyei Yul Ryu; Kwang Jin Jung; Jong Yoon Jung; Gyu Ho Hwang; Sang Hag Lee Journal: J Allergy Clin Immunol Date: 2013-01-30 Impact factor: 10.793
Authors: Nicholas Van Bruaene; Claudina Angela Pérez-Novo; Tomasz M Basinski; Thibaut Van Zele; Gabriele Holtappels; Natalie De Ruyck; Carsten Schmidt-Weber; Cezmi Akdis; Paul Van Cauwenberge; Claus Bachert; Philippe Gevaert Journal: J Allergy Clin Immunol Date: 2008-06 Impact factor: 10.793